The US Food and Drug Administration has approved Sanofi’s oral drug Infilbray for neurological symptoms linked to type 3 Gaucher disease, a rare inherited disorder affecting the brain and nervous system.
Infilbray, also known as venglustat, is the first treatment specifically approved for these symptoms in patients weighing at least 15kg (33lb), the FDA said.
Type 3 Gaucher disease prevents the body from properly breaking down glucosphingolipids, causing fatty substances to accumulate in organs, tissues and the brain. Unlike type 1 Gaucher disease, it can lead to progressive problems with balance, coordination, speech, memory and thinking.
Sanofi’s tablet works by inhibiting glucosylceramide synthase, reducing the build-up of the harmful substances. The FDA said the drug can cross the blood-brain barrier, allowing it to act on the neurological effects of the condition.
“For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug’s ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms,” acting FDA commissioner Kyle Diamantas said.
“This approval reflects the FDA’s commitment to advancing therapeutic options for patients with rare diseases and brings an important new treatment to patients and the healthcare providers who care for them,” he added.
Study data behind FDA approval
The decision was supported by a clinical study involving 43 patients aged 12 and over with type 3 Gaucher disease. All had previously received enzyme replacement therapy and achieved stabilisation of their systemic disease.
Participants were given either Infilbray once a day or intravenous enzyme replacement therapy every two weeks for 52 weeks.
Researchers assessed neurological symptoms affecting daily life, including loss of muscle control and coordination, known as ataxia, as well as cognitive function. After 52 weeks, patients taking Infilbray showed improvement on a measure combining the two assessments compared with those receiving enzyme replacement therapy for non-neurological symptoms.
The most commonly reported side effects included digestive problems and changes in mood. The FDA also warned of serious psychiatric risks, including suicidal thoughts and behaviour.
Animal studies identified possible vision clouding in younger patients and harmful effects on fetal development, the agency said.
Sanofi already markets Cerdelga for type 1 Gaucher disease and Cerezyme for symptoms outside the brain and nervous system in patients with types 1 and 3. Infilbray is also under regulatory review for type 3 Gaucher disease in the European Union and Japan.
